Insulin resistance, diabetes, and atherosclerosis: Thiazolidinediones as therapeutic interventions

Current Cardiology Reports

Volumn 4, Issue 6, 2002, Pages 514-521

  Raji, Annaswamy ^a   Plutzky, Jorge ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; CELL RECEPTOR; CHROMAN DERIVATIVE; LIPOPROTEIN; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR; TROGLITAZONE;

ADIPOSE TISSUE; ANIMAL; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHY; HUMAN; INSULIN RESISTANCE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ADIPOSE TISSUE; ANIMALS; CHROMANS; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPOPROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0036832761     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-002-0116-3     Document Type: Article

References (120)

1. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al.: Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001, 134:61-71.
2. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
3. Deedwania PC: The deadly quartet revisited. Am J Med 1998, 105:1S-3S.
4. Owen P, Evans M: Therapy and clinical trials: type 2 diabetes: lifestyle and beyond. Curr Opin Lipidol 2002, 13:351-353.
5. Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published erratum appears in N Engl J Med 1997, 337:356]. N Engl J Med 1997, 336:973-979.
6. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995, 44:968-983.
7. Nathan DM: Prevention of long-term complications of noninsulin- dependent diabetes mellitus. Clin Invest Med 1995, 18:332-339.
8. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1999, 354:602]. Lancet 1998, 352:837-853.
9. Adler AI, Neil HA, Manley SE, et al.: Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). Am Heart J 1999, 138:353-359.
10. Haffner SM, Miettinen H: Insulin resistance implications for type II diabetes mellitus and coronary heart disease [see comments]. Am J Med 1997, 103:152-162.
11. Strong JP, Malcom GT, McMahan CA, et al.: Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999, 281:727-735.
12. Tuzcu EM, Kapadia SR, Tutar E, et al.: High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001, 103:2705-2710.
13. McGill HC Jr., McMahan CA, Zieske AW, et al.: Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation 2001, 103:1546-1550.
14. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999, 354:617-621.
15. Balkau B: The DECODE study. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Diabetes Metab 2000, 26:282-286.
16. Ginsberg H, Plutzky J, Sobel BE: A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk 1999, 6:337-346.
17. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131:281-303.
18. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002, 287:360-372.
19. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1998, 352:1557]. Lancet 1998, 352:854-865.
20. Henry RR: Thiazolidinediones. Endocrinol Metab Clin North Am 1997, 26:553-573.
21. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435.
22. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527-550.
23. Bergman RN: Troglitazone. Drugs 1997, 54:89-101, discussion 102.
24. Komers R, Vrana A: Thiazolidinediones-tools for the research of metabolic syndrome X. Physiol Res 1998, 47:215-225.
25. Berger J, Leibowitz MD, Doebber TW, et al.: Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 1999, 274:6718-6725.
26. Schoonjans K, Martin G, Staels B, Auwerx J: Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997, 8:159-166.
27. Spiegelman BM: Peroxisome proliferator-activated receptor gamma: A key regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res 1997, 2:457-464.
28. Bahr M, Spelleken M, Bock M, et al.: Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes. Diabetologia 1996, 39:766-774.
29. Ciaraldi TP, Huber Knudsen K, Hickman M, Olefsky JM: Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism 1995, 44:976-981.
30. De Vos P, Lefebvre AM, Miller SG, et al.: Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 1996, 98:1004-1009.
31. Ohsumi J, Sakakibara S, Yamaguchi J, et al.: Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 1994, 135:2279-2282.
32. Szalkowski D, White Carrington S, Berger J, Zhang B: Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulinstimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 1995, 136:1474-1481.
33. Day C: Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999, 16:179-192.
34. Lehmann JM, Moore LB, Smith-Oliver TA, et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J Biol Chem 1995, 270:12953-12956.
35. Lambe KG, Tugwood JD: A human peroxisome-proliferatoractivated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem 1996, 239:1-7.
36. Spiecker M, Peng HB, Liao JK: Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of Ikappa- Balpha. J Biol Chem 1997, 272:30969-30974.
37. Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47:507-514.
38. Forman BM, Tontonoz P, Chen J, et al.: 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83:803-812.
39. Matthaei S, Stumvoll M, Kellerer M, Haring HU: Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000, 21:585-618.
40. Burant CF, Sreenan S, Hirano K, et al.: Troglitazone action is independent of adipose tissue. J Clin Invest 1997, 100:2900-2908.
41. Randle PJ, Priestman DA, Mistry SC, Halsall A: Glucose fatty acid interactions and the regulation of glucose disposal. J Cell Biochem 1994, 55:1-11.
42. Saloranta C, Groop L: Interactions between glucose and FFA metabolism in man. Diabetes Metab Rev 1996, 12:15-36.
43. Ciaraldi TP, Abrams L, Nikoulina S, et al.: Glucose transport in cultured human skeletal muscle cells. Regulation by insulin and glucose in nondiabetic and non-insulindependent diabetes mellitus subjects. J Clin Invest 1995, 96:2820-2827.
44. Tafuri SR: Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. Endocrinology 1996, 137:4706-4712.
45. Ciaraldi TP, Gilmore A, Olefsky JM, et al.: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990, 39:1056-1062.
46. Nolan JJ, Ludvik B, Beerdsen P, et al.: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994, 331:1188-1193.
47. Kroder G, Bossenmaier B, Kellerer M, et al.: Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. J Clin Invest 1996, 97:1471-1477.
48. Hofmann C, Lorenz K, Braithwaite SS, et al.: Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994, 134:264-270.
49. Kallen CB, Lazar MA: Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1996, 93:5793-5796.
50. Keller JM, Collet P, Bianchi A, et al.: Implications of peroxisome proliferator-activated receptors (PPARS) in development, cell life status and disease. Int J Dev Biol 2000, 44:429-442.
51. Lee MK, Miles PD, Khoursheed M, et al.: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1994, 43:1435-1439.
52. O'Rourke CM, Davis JA, Saltiel AR, Cornicelli JA: Metabolic effects of troglitazone in the Goto-Kakizaki rat, a nonobese and normolipidemic rodent model of non-insulindependent diabetes mellitus. Metabolism 1997, 46:192-198.
53. Masuda K, Okamoto Y, Tsuura Y, et al.: Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 1995, 38:24-30.
54. Suter SL, Nolan JJ, Wallace P, et al.: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992, 15:193-203.
55. Antonucci T, Whitcomb R, McLain R, et al.: Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997, 20:188-193.
56. Dunaif A, Scott D, Finegood D, et al.: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81:3299-3306.
57. Maggs DG, Buchanan TA, Burant CF, et al.: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo- controlled trial. Ann Intern Med 1998, 128:176-185.
58. Inzucchi SE, Maggs DG, Spollett GR, et al.: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus [see comments]. N Engl J Med 1998, 338:867-872.
59. Berkowitz K, Peters R, Kjos SL, et al.: Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes 1996, 45:1572-1579.
60. Patel J, Anderson RJ, Rappaport EB: Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999, 1:165-172.
61. Aronoff S, Rosenblatt S, Braithwaite S, et al.: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000, 23:1605-1611.
62. Phillips LS, Grunberger G, Miller E, et al.: Once- and twicedaily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001, 24:308-315.
63. Peters AL: Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice. Am J Manag Care 2001, 7:S87-S95.
64. Greene DA: Rosiglitazone: a new therapy for type 2 diabetes. Expert Opin Invest Drugs 1999, 8:1709-1719.
65. Kipnes MS, Krosnick A, Rendell MS, et al.: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001, 111:10-17.
66. Lebovitz HE, Dole JF, Patwardhan R, et al.: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001, 86:280-288.
67. Nolan JJ, Jones NP, Patwardhan R, Deacon LF: Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000, 17:287-294.
68. Raskin P, Rappaport EB, Cole ST, et al.: Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000, 43:278-284.
69. Einhorn D, Rendell M, Rosenzweig J, et al.: Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebocontrolled study. The Pioglitazone 027 Study Group. Clin Ther 2000, 22:1395-1409.
70. Fonseca V, Rosenstock J, Patwardhan R, Salzman A: Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000, 283:1695-1702.
71. Kumar S, Prange A, Schulze J, et al.: Troglitazone, an insulin action enhancer, improves glycemic control and insulin sensitivity in elderly type 2 diabetic patients. Diabet Med 1998, 15:772-779.
72. Horton ES, Whitehouse F, Ghazzi MN, et al.: Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care 1998, 21:1462-1469.
73. Iwamoto Y, Kosaka K, Kuzuya T, et al.: Effect of combination therapy of troglitazone and sulfonylureas in patients with Type 2 diabetes who were poorly controlled by sulfonylurea therapy alone. Diabet Med 1996, 13:365-370.
74. Steinberg D, Parthasarathy S, Carew TE, et al.: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
75. Chait A, Brazg RL, Tribble DL, Krauss RM: Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993, 94:350-356.
76. Austin MA: Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. Am J Epidemiol 1989, 129:249-259.
77. Fujiwara T, Yoshioka S, Yoshioka T, et al.: Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988, 37:1549-1558.
78. Ikeda H, Taketomi S, Sugiyama Y, et al.: Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 1990, 40:156-162.
79. Oakes ND, Kennedy CJ, Jenkins AB, et al.: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994, 43:1203-1210.
80. Ghazzi MN, Perez JE, Antonucci TK, et al.: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997, 46:433-439.
81. Product Insert Information, 2002.
82. Goldstein BJ: Rosiglitazone. Int J Clin Pract 2000, 54:333-337.
83. King AB: A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000, 23:557.
84. Sakamoto J, Kimura H, Moriyama S, et al.: Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000, 278:704-711.
85. Yoshioka S, Nishino H, Shiraki T, et al.: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 1993, 42:75-80.
86. Tack CJ, Smits P, Demacker PN, Stalenhoef AF: Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998, 21:796-799.
87. Noguchi N, Sakai H, Kato Y, et al.: Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 1996, 123:227-234.
88. Cominacini L, Garbin U, Fratta Pasini A, et al.: Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 1998, 47:130-133.
89. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
90. Plutzky J: Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep 2000, 2:327-335.
91. Bishop-Bailey D: Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000, 129:823-834.
92. Glass CK, Witztum JL: Atherosclerosis the road ahead. Cell 2001, 104:503-516.
93. Marx N, Schonbeck U, Lazar MA, et al.: Peroxisome proliferatoractivated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998, 83:1097-1103.
94. Marx N, Sukhova G, Murphy C, et al.: Macrophages in human atheroma contain PPARgamma: differentiation- dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998, 153:17-23.
95. Ricote M, Li AC, Willson TM, et al.: The peroxisome proliferator- activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
96. Plutzky J: Atherosclerotic plaque rupture: emerging insights and opportunities. Am J Cardiol 1999, 84:15J-20J.
97. Goetze S, Xi XP, Kawano H, et al.: PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 1999, 33:798-806.
98. Tontonoz P, Nagy L, Alvarez JG, et al.: PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93:241-252.
99. Spiegelman BM: PPARgamma in monocytes: less pain, any gain? Cell 1998, 93:153-155.
100. Minamikawa J, Tanaka S, Yamauchi M, et al.: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998, 83:1818-1820.
101. Koshiyama H, Shimono D, Kuwamura N, et al.: Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001, 86:3452.
102. Jackson SM, Parhami F, Xi XP, et al.: Peroxisome proliferatoractivated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999, 19:2094-2104.
103. Pasceri V, Wu HD, Willerson JT, Yeh ET: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101:235-238.
104. Marx N, Sukhova GK, Collins T, et al.: PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999, 99:3125-3131.
105. Ricote M, Huang J, Fajas L, et al.: Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998, 95:7614-7619.
106. Seed B: PPARgamma and colorectal carcinoma: conflicts in a nuclear family [news, comment]. Nat Med 1998, 4:1004-1005.
107. Marx N, Mach F, Sauty A, et al.: Peroxisome proliferatoractivated receptor-gamma activators inhibit IFN- gammainduced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000, 164:6503-6508.
108. Han KH, Chang MK, Boullier A, et al.: Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J Clin Invest 2000, 106:793-802.
109. Kintscher U, Kon D, Wakino S, et al.: Doxazosin inhibits monocyte chemotactic protein 1-directed migration of human monocytes. J Cardiovasc Pharmacol 2001, 37:532-539.
110. Wu GD: A nuclear receptor to prevent colon cancer. N Engl J Med 2000, 342:651-653.
111. Yang XY, Wang LH, Chen T, et al.: Activation of human T lymphocytes is inhibited by peroxisome proliferatoractivated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000, 275:4541-4544.
112. Harris SG, Phipps RP: The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol 2001, 31:1098-1105.
113. Kwak BR, Myit S, Mulhaupt F, et al.: PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheromaassociated cells. Circ Res 2002, 90:356-362.
114. Yang XY, Wang LH, Mihalic K, et al.: Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands. J Biol Chem 2002, 277:3973-3978.
115. Marx N, Kehrle B, Kohlhammer K, et al.: PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantationassociated arteriosclerosis. Circ Res 2002, 90:703-710.
116. Li AC, Brown KK, Silvestre MJ, et al.: Peroxisome proliferatoractivated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000, 106:523-531.
117. Chen Z, Ishibashi S, Perrey S, et al.: Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001, 21:372-377.
118. Collins AR, Meehan WP, Kintscher U, et al.: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:365-371.
119. Claudel T, Leibowitz MD, Fievet C, et al.: Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 2001, 98:2610-2615.
120. Takagi T, Yamamuro A, Tamita K, et al.: Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002, 89:318-322.